During this year’s World Vaccine Congress, Velocity Clinical Research will host an exclusive “Dine and Discuss” dinner bringing together a select group of senior leaders from across the vaccine and clinical research ecosystem for an off-the-record conversation with vaccine policy and law expert Richard … Read more
There is a logic to the way William Cromwell, MD speaks about cardiometabolic risk — if this, then that. But you never feel as though it would come at the expense of the person sitting opposite him. Over the past 35 years of specialty … Read more
By Evelyne Newton, Business Development Europe at Velocity Clinical Research Next week I will join industry leaders to explore one of the most pressing questions facing sites across Europe: how can clinical trial sites diversify therapeutic areas sustainably without compromising quality? In a competitive … Read more
By Andrew Reina, Chief Revenue Officer Clinical research is at an inflection point. Sponsors and CROs are being asked to deliver trials that start faster, enrol more predictably, and generate data that stands up to increasing regulatory and commercial scrutiny. In that environment, long-standing … Read more
Over the course of his career, Matthew Wenker, MD, has moved from hospital wards to Phase I units and, eventually, to leading research across three Velocity sites in Cincinnati. Along the way, he has been Principal Investigator (PI) or sub-investigator on close to 500 … Read more
Across multiple Phase 3 trials, Eli Lilly and Company’s once-weekly insulin efsitora alfa matched daily basal insulin in A1C reduction and demonstrated a similar safety profile. “The novel fixed-dose regimen … has the potential to facilitate and simplify insulin therapy, reducing the hesitation often … Read more
Congratulations to the Structure Therapeutics team for announcing positive topline data from its ACCESS clinical program for aleniglipron, an oral GLP-1 receptor agonist. Julio Rosenstock, MD, Chair of the ACCESS program Steering Committee and Senior Scientific Advisor at Velocity, is quoted in the press … Read more
Henrik Watz, MD, PhD, is the chief investigator and author of trial results for EpiEndo’s clinical trial of glasmacinal (EP395). Results indicated that glasmacinal reduced neutrophilic inflammation in COPD patients without any detectable impact on the lung microbiome, supporting preclinical findings of reduced antimicrobial … Read more
When you first meet Fritz Raiser, DO, you could be forgiven for thinking he was on holiday. There’s a quiet ease about him, a calm confidence that feels almost out of place for someone who spends half his week in a busy emergency room … Read more
At ObesityWeek in Atlanta, Stanley Hsia, MD, presented results from a Phase 2 Eli Lilly/Innovent Biologics study of mazdutide, a once-weekly injectable GLP-1/glucagon dual agonist. The study demonstrated dose-dependent weight loss. Dr. Hsia: “All of these mazdutide treatment curves did not seem to plateau, … Read more
Velocity Clinical Research, the leading fully integrated site organization, today announces the appointment of Andrew (Drew) Reina as Chief Revenue Officer (CRO), effective immediately. Drew joins from Fortrea, one of the world’s leading contract research organizations (CROs), where he held senior leadership roles driving … Read more
A research career wasn’t part of Gerald Cephas, MD’s original plan. He trained in general surgery, intending to specialize in pediatrics, but a health setback during residency changed his course. “Toward the end of residency, I got sick,” he explains. “So, long story short, … Read more
Learn more about Velocity's capabilities
Whether you’re ready to conduct a single-site study or a complex, high-volume trial, Velocity will ensure you have the right investigators, clinical staff, and patients for your research program.
Join a remarkable team doing remarkable work
Velocity careers offer competitive pay and benefits, and reward high performance with excellent opportunities.
Whether you're an industry veteran or are looking to take your first step into clinical research, we invite you to apply at Velocity.